<DOC>
	<DOCNO>NCT01179854</DOCNO>
	<brief_summary>The purpose study determine weather different dos Remegal effective , safety tolerant Additional Therapy Patients With Refractory Partial Seizures pharmacokinetics definition</brief_summary>
	<brief_title>Remegal Different Doses Patients With Refractory Partial Seizures</brief_title>
	<detailed_description>Phase II</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<criteria>1 . Subject report partial onset seizure least last 2 year despite prior therapy least 2 different consecutive AEDs . 2 . Subject report average least 4 partial onset seizure per 28 day prior entry Baseline phase . 3 . Seizurefree period longer 21 day 4week period prior entry Baseline phase . 4 . Subject stable dosage regimen maximum 3 AEDs , . 5 . The dosage concomitant AED therapy keep constant least 4 week prior entry Baseline phase . 6 . ` Subject receive information give time think participation give write informed consent . 7 . Subject male female 18 65 year old . 8 . Subject diagnosis epilepsy simple partial seizure and/or complexpartial seizure without secondary generalization accord ILAE ( 1981 ) : The result least one prior electroencephalogram ( EEG ) magnetic resonance imaging/computerized tomography scan consistent diagnosis partial seizure . In case simple partial seizure , motor sign include . 1 . Subject nonepileptic event include psychogenic seizure could confuse seizure . 2 . Subject seizure count due clustering . 3 . Subject history primary generalized seizure . 4 . Subject history status epilepticus within 12 month period prior trial entry . 5 . Subject concomitant treatment felbamate previous felbamate therapy within last 6 month prior trial entry . 6 . Subject concomitant treatment vigabatrin . Subjects previous vigabatrin therapy must visual field test prior trial entry . 7 . Subject progressive structural lesion central nervous system progressive encephalopathy . 8 . Subject receive REMEGAL previous trial . 9 . Subject currently participate participate within last two month trial investigational drug experimental device . 10 . Pregnant nursing woman and/or childbearing potential surgically sterile , two year postmenopausal practice two combine method contraception , unless sexually abstinent , duration trial . 11 . Subject medical psychiatric condition , opinion investigator could jeopardize subject 's health would compromise subject 's ability participate trial . 12 . Subject history chronic alcohol drug abuse within previous 2 year . 13 . Subject alanine amino transferase ( ALT ) , aspartate amino transferase ( AST ) , alkaline phosphatase , total bilirubin , serum creatinine level equal 2 time upper limit normal . 14 . Subject clinically significant abnormal vital sign . 15 . Subject known history severe anaphylactic reaction serious blood dyscrasia . 16 . Subject clinically significant disease , surgical condition recent chronic consumption nonAED medication ( within precede four week prior trial entry ) might reasonably expect interfere drug absorption , distribution , metabolism excretion . 17 . Subject take one follow medication influence central nervous system within four week prior trial entry : neuroleptic , monoamine oxidase ( MAO ) inhibitor , anxiolytic , amphetamine , sedative antihistamine , tranquilizer , hypnotic , narcotic analgesic , except medication take epileptic treatment . 18 . Subject confirm clinically significant abnormality ECG , include prolonged QTc interval .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>